keyword
MENU ▼
Read by QxMD icon Read
search

Dmard therapy

keyword
https://www.readbyqxmd.com/read/28649878/safety-and-effectiveness-of-tacrolimus-add-on-therapy-for-rheumatoid-arthritis-patients-without-an-adequate-response-to-biological-disease-modifying-anti-rheumatic-drugs-dmards-post-marketing-surveillance-in-japan
#1
Tsutomu Takeuchi, Kota Ishida, Katsuhisa Shiraki, Takashi Yoshiyasu
OBJECTIVES: Post-marketing surveillance (PMS) was conducted to assess the safety and effectiveness of tacrolimus (TAC) add-on therapy for patients with rheumatoid arthritis (RA) and an inadequate response to biological disease-modifying anti-rheumatic drugs (DMARDs). METHODS: Patients with RA from 180 medical sites across Japan were registered centrally with an electronic investigation system. The observational period was 24 weeks from the first day of TAC administration concomitantly with biological DMARDs...
June 26, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28646434/performance-of-quantiferon-%C3%A2-tb-gold-in-tube-assay-in-children-receiving-disease-modifying-anti-rheumatic-drugs
#2
Francesca Gabriele, Maria Trachana, Maria Simitsopoulou, Polixeni Pratsidou-Gertsi, Elias Iosifidis, Zoi Dorothea Pana, Emmanuel Roilides
BACKGROUND: To evaluate the performance of the Quantiferon(®)-TB Gold In-Tube (QFT-IT) interferon (IFN)-γ assay for the detection of latent tuberculosis infection (LTBI) in children receiving anti-rheumatic treatment in a tertiary referral hospital of Northern Greece. METHODS: A total of 79 consecutive children receiving anti-rheumatic treatment [of which 18 screened prior to antitumor necrosis factor (TNF)-α treatment] were tested using Mantoux tuberculin skin test (TST) and QFT-IT...
June 22, 2017: World Journal of Pediatrics: WJP
https://www.readbyqxmd.com/read/28644744/add-on-iguratimod-as-a-therapeutic-strategy-to-achieve-remission-in-patients-with-rheumatoid-arthritis-inadequately-responding-to-biological-dmards-a-retrospective-study
#3
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi, Shigeki Makino
OBJECTIVES: In this study, iguratimod (IGU) was added to rheumatoid arthritis (RA) patients inadequately responding to 24-week or longer treatment with biological disease-modifying antirheumatic drug (bDMARDs), its effectiveness was assessed, and factors contributing to remission were evaluated. METHODS: RA patients who fulfilled the following criteria were included: (i) ≥ 24-week of bDMARDs; (ii) 2.6 < disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR) < 5...
June 23, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28638693/management-of-the-temporomandibular-joint-in-inflammatory-arthritis-involvement-of-surgical-procedures
#4
REVIEW
Rory C O'Connor, Fiona Fawthrop, Rami Salha, Andrew J Sidebottom
Many conditions may affect the temporomandibular joint (TMJ), but its incidence in individual joint diseases is low. However, inflammatory arthropathies, particularly rheumatoid and psoriatic arthritis and ankylosing spondylitis, appear to have a propensity for affecting the joint. Symptoms include pain, restriction in mouth opening, locking, and noises, which together can lead to significant impairment. Jaw rest, a soft diet, a bite splint, and medical therapy, including disease-modifying antirheumatic drugs (DMARDs) and simple analgesia, are the bedrock of initial treatment and will improve most symptoms in most patients...
June 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/28634103/undetectable-mannose-binding-lectin-and-corticosteroids-increase-serious-infection-risk-in-rheumatoid-arthritis
#5
Graeme J Carroll, Krista Makin, Maxine Garnsey, Max Bulsara, Bronwyn V Carroll, Shona M Curtin, Erin M Allan, Andrew McLean-Tooke, Christine Bundell, Monica L Kemp, Pooja Deshpande, Dana Ihdayhid, Sophie Coleman, Tracie Easter, James Triplett, Timothy Disteldorf, C Helen Marsden, Michaela Lucas
BACKGROUND: Infection is the leading cause of death in rheumatoid arthritis (RA). Corticosteroid (CS) use is a known and important risk factor for serious infections (SIs). Mannose binding lectin (MBL) is a genetically determined component of the innate immune system implicated in neonatal infections. OBJECTIVE: Our aim was to determine whether MBL deficiency is a risk factor for SIs in RA and to compare it with CS use and also synthetic and biologic disease-modifying antirheumatic drug (DMARD) therapy...
June 17, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28630629/the-cedar-study-a-longitudinal-study-of-the-clinical-effects-of-conventional-dmards-and-biologic-dmards-in-australian-rheumatology-practice
#6
Lynden Roberts, Kathleen Tymms, Julien de Jager, Geoffrey Littlejohn, Hedley Griffiths, Dave Nicholls, Paul Bird, Jennifer Young, Julie Hill, Jane Zochling
OBJECTIVES: To observe the choices of conventional disease modifying antirheumatic drugs (cDMARDs) and biologic DMARDs (bDMARDs) in the management of rheumatoid arthritis (RA) in Australian routine clinical practice, to assess treatment survival and determine the effect of cDMARDs/bDMARDs on disease activity. METHODS: Routinely collected, deidentified clinical data was sourced from 20 Australian rheumatology practices. RA patients aged ≥18 years, who had received cDMARDs/bDMARDs and a recorded subsequent visit, were included...
2017: International Journal of Rheumatology
https://www.readbyqxmd.com/read/28615732/managing-rheumatic-and-musculoskeletal-diseases-past-present-and-future
#7
REVIEW
Gerd R Burmester, Johannes W J Bijlsma, Maurizio Cutolo, Iain B McInnes
Progress in rheumatology has been remarkable in the past 70 years, favourably affecting quality of life for people with rheumatic and musculoskeletal diseases. Therapeutics have advanced considerably in this period, from early developments such as the introduction of glucocorticoid therapy to the general use of methotrexate and other disease-modifying agents, followed by the advent of biologic DMARDs and, most recently, small-molecule signalling inhibitors. Novel strategies for the use of such agents have also transformed outcomes, as have multidisciplinary nonpharmacological approaches to the management of rheumatic musculoskeletal disease including surgery, physical therapy and occupational therapy...
July 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28615036/predictors-of-the-response-to-etanercept-in-patients-with-juvenile-idiopathic-arthritis-without-systemic-manifestations-within-12-months-results-of-an-open-label-prospective-study-conducted-at-the-national-scientific-and-practical-center-of-children-s-health
#8
Ekaterina I Alexeeva, Leyla S Namazova-Baranova, Tatyana M Bzarova, Saniya I Valieva, Rina V Denisova, Tatyana V Sleptsova, Kseniya B Isaeva, Alexandra M Chomahidze, Nikolay I Taibulatov, Anna N Fetisova, Anna V Karaseva, Alexandr A Baranov
BACKGROUND: The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations. METHODS: A total of 197 juvenile patients were enrolled in this study. Response to therapy was assessed using the ACRPedi 30/50/70/90 criteria, the Wallace criteria, and the Juvenile Arthritis Disease Activity Score 71 (JADAS-71)...
June 14, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/28608166/abatacept-a-review-in-rheumatoid-arthritis
#9
Hannah A Blair, Emma D Deeks
The biological DMARD (bDMARD) abatacept (Orencia(®)), a recombinant fusion protein, selectively modulates a co-stimulatory signal necessary for T-cell activation. In the EU, abatacept is approved for use in patients with highly active and progressive rheumatoid arthritis (RA) not previously treated with methotrexate. Abatacept is also approved for the treatment of moderate to severe active RA in patients with an inadequate response to previous therapy with at least one conventional DMARD (cDMARD), including methotrexate or a TNF inhibitor...
June 12, 2017: Drugs
https://www.readbyqxmd.com/read/28598787/severe-adverse-drug-reactions-to-biological-disease-modifying-anti-rheumatic-drugs-in-elderly-patients-with-rheumatoid-arthritis-in-clinical-practice
#10
Leticia Leon, Alejandro Gomez, Cristina Vadillo, Esperanza Pato, Luis Rodriguez-Rodriguez, Juan Angel Jover, Lydia Abasolo
OBJECTIVES: Biological DMARDs are widely used in the treatment of rheumatoid arthritis (RA) but their relationship with adverse drug reaction (ADR) is important. RA is now known to increase in incidence and prevalence with age. Our objective was to assess the incidence of severe ADR in the long term, compare safety between the different bDMARDs and identify other possible risk factors for severe ADR in elderly RA patients. METHODS: A 14-year retrospective longitudinal study was performed...
June 6, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28598774/what-could-we-learn-from-the-sub-analysis-of-a-single-nation-cohort-in-a-worldwide-study-lessons-from-the-results-observed-in-the-italian-cohort-of-the-go-more-trial
#11
Roberto Giacomelli, Piero Ruscitti, Stefano Bombardieri, Giovanna Cuomo, Salvatore De Vita, Mauro Galeazzi, Monica Mecchia
OBJECTIVES: GO-MORE Trial investigated the use of Golimumab (GLM) in 3280 rheumatoid arthritis (RA) patients worldwide. At present, the burden of arthritis is greater in poorer countries than in developed countries due to socioeconomic disparities, thus suggesting the usefulness of subgroup investigations. We aimed to evaluate GLM as add-on therapy for RA patients in the Italian cohort of GO-MORE trial and compared the clinical characteristics between Italian patients and the enrolled patients worldwide...
June 6, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28597306/maintenance-of-remission-with-combination-etanercept-dmard-therapy-versus-dmards-alone-in-active-rheumatoid-arthritis-results-of-an-international-treat-to-target-study-conducted-in-regions-with-limited-biologic-access
#12
Karel Pavelka, Nurullah Akkoç, Mustafa Al-Maini, Cristiano A F Zerbini, Dmitry E Karateev, Evgeny L Nasonov, Mahboob U Rahman, Ronald Pedersen, Andrew Dinh, Qi Shen, Radu Vasilescu, Sameer Kotak, Ehab Mahgoub, Bonnie Vlahos
In this transglobal, randomized, double-blind, placebo-controlled, treat-to-target study, the maintenance of efficacy was compared between biologic-and biologic-free-disease-modifying antirheumatic drug (DMARD) combination regimens after low disease activity (LDA) was achieved with biologic DMARD induction therapy. Patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy received open-label etanercept 50 mg subcutaneously once weekly plus methotrexate with or without other conventional synthetic (cs) DMARDs for 24 weeks...
June 9, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28583690/transition-to-adult-rheumatology-care-is-necessary-to-maintain-dmard-therapy-in-young-people-with-juvenile-idiopathic-arthritis
#13
Andres Luque Ramos, Falk Hoffmann, Katinka Albrecht, Jens Klotsche, Angela Zink, Kirsten Minden
OBJECTIVE: To evaluate the outpatient health service utilisation of young people (YP) with juvenile idiopathic arthritis (JIA) during transfer from paediatric to adult care in Germany. METHODS: Based on claims data of a large German statutory health fund (BARMER GEK) we conducted a cohort study of 2008-2014. Insured YP with diagnosis of JIA (ICD: M08 or M09.0) in two quarters at the age of 16 and continuous insurance until the age of 20 were included. Outpatient health care utilisation, prescribed antirheumatic drugs and diagnosis maintenance were analysed over four consecutive years for all YP with JIA and for the subgroup on disease-modifying antirheumatic drugs (DMARDs) at the age of 16...
May 12, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28583061/infection-after-total-knee-arthroplasty-by-m-catarrhalis-associated-with-rheumatoid-arthritis-and-dmards-therapy
#14
Perry Evangelista, Gregory Evangelista, Lauren Ogrich
Moraxella catarrhalis is not commonly associated with prosthetic joint infection (PJI). We present the first case of a patient with rheumatoid arthritis on certolizumab, an antitumor necrosis factor therapy, who developed PJI following a total knee replacement.
April 2017: Bulletin of the Hospital for Joint Diseases
https://www.readbyqxmd.com/read/28570437/identification-and-validation-of-clinically-relevant-clusters-of-severe-fatigue-in-rheumatoid-arthritis
#15
Neil Basu, Gareth T Jones, Gary J Macfarlane, Katie L Druce
OBJECTIVE: The considerable heterogeneity of rheumatoid arthritis (RA) related fatigue is the greatest challenge to determining pathogenesis. The identification of homogenous sub-types of severe fatigue would inform the design and analysis of experiments seeking to characterise the likely numerous causal pathways which underpin the symptom. This study aimed to identify and validate such fatigue sub-types in patients with RA. METHODS: Data were obtained from patients recruited to the British Society for Rheumatology Biologics register for RA, as either receiving traditional Disease Modifying Anti-Rheumatic Drugs (DMARD cohort, n=522) or commencing anti-TNF therapy (anti-TNF cohort, n=3909)...
May 31, 2017: Psychosomatic Medicine
https://www.readbyqxmd.com/read/28552625/the-current-status-and-unmet-needs-in-the-management-of-psoriatic-arthritis-viewpoint-from-physicians-in-taiwan
#16
Tzu-Hao Li, Hsien-Tzung Liao, Yi-Fan Huang, Yu-Chuan Shen, Yao-Chang Chiu, Wei-Sheng Chen, Ming-Han Chen, Chang-Youh Tsai, Deh-Ming Chang
BACKGROUND/PURPOSE: To analyze the real-world clinical practice for the treatment of psoriatic arthritis (PsA) and to assess physicians' prescription, difficulties in diagnosis, therapeutic strategy, rationales for biologic therapies and unmet needs in Taiwan. METHODS: We conducted a nationwide cross-sectional observational study by face-to-face in depth interviews with 50 rheumatologists and 30 dermatologists who took care of patients with PsA. RESULTS: The major procedures for recognizing PsA included joint, skin and nail examinations, radiographic imaging, and medical history...
May 25, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28552512/immune-response-to-pneumococcal-conjugate-vaccine-in-patients-with-systemic-vasculitis-receiving-standard-of-care-therapy
#17
Per Nived, Johanna Nagel, Tore Saxne, Pierre Geborek, Göran Jönsson, Lillemor Skattum, Meliha C Kapetanovic
AIM: To study the effect of standard of care therapy on antibody response and functionality following immunization with 13-valent pneumococcal conjugate vaccine (PCV13) in patients with primary systemic vasculitis compared to healthy controls. METHODS: 49 patients with vasculitis and 49 controls received a single dose (0.5ml) PCV13 intramuscularly. Ongoing treatments: azathioprine (AZA; n=11), cyclophosphamide (CYC; n=6), methotrexate (MTX; n=9), rituximab (n=3); anti-TNF (n=2), mycophenolate mofetil (n=2), prednisolone alone (n=15) and no active treatment (n=2)...
June 22, 2017: Vaccine
https://www.readbyqxmd.com/read/28526972/patient-experiences-attitudes-and-expectations-towards-receiving-information-about-anti-tnf-medication-a-quantitative-study
#18
Jon Packham, Paul Arkell, Tom Sheeran, Ann Brownfield, Anthony Cadwgan, Sarah Ryan
The objective of the study was to measure patient attitudes and experience of information received during drug counselling for rheumatoid arthritis (RA) medications. This is a cross-sectional UK postal questionnaire study. Three RA patient groups-disease-modifying antirheumatic drugs (DMARDs) only, first anti-tumour necrosis factor (anti-TNF) and failed anti-TNF-were sent postal questionnaires. Data on patient history/demographics, drug counselling experience, knowledge of drug side effects, attitudes to vaccinations, cancer screening and blood borne virus testing was collected; 264/679 (39%) patients responded (median age 65 years, 66% female, median disease duration 15 years)...
May 19, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28524619/use-of-complementary-and-alternative-medicines-is-associated-with-delay-to-initiation-of-disease-modifying-anti-rheumatic-drug-therapy-in-early-inflammatory-arthritis
#19
Manjari Lahiri, Amelia Santosa, Lay Kheng Teoh, Jane A Clayton, Sheen Yee Lim, Gim Gee Teng, Peter P M Cheung
OBJECTIVES: To study the predictors of complementary and alternative medicine (CAM) use in patients with early inflammatory arthritis (EIA), and its impact on delay to initiation of disease-modifying anti-rheumatic drugs (DMARD). METHODS: Data were collected prospectively from EIA patients aged ≥ 21 years. Current or prior CAM use was ascertained by face-to-face interview. Predictors of CAM use and its effect on time to DMARD initiation were determined by multivariate logistic regression and Cox proportional hazards, respectively...
May 19, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28521841/tnf-inhibitors-appear-to-inhibit-disease-progression-and-improve-outcome-in-takayasu-arteritis-an-observational-population-based-time-trend-study
#20
Birgir Gudbrandsson, Øyvind Molberg, Øyvind Palm
BACKGROUND: Magnetic resonance imaging (MRI) and computed tomography (CT) angiography have now largely replaced interventional angiography in the diagnoses and follow up of Takayasu arteritis (TAK) but data on the effects of this change of imaging method on diagnostic delay and vascular damage, and detailed data on the effect of different treatment regimens on the accumulation of vascular damage are missing. The aim of this study was to assess time trends in diagnostic delay, therapeutic approaches, arterial lesion accrual, persistent disease activity and remission rates in TAK...
May 18, 2017: Arthritis Research & Therapy
keyword
keyword
2404
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"